- HEMISPHERx has begun a Phase II trial with Ampligen (poly I: polyC12U) in untreated HIV patients with CD4 levels over 400 cells/mm3. Previous studies have shown that HIV patients with CD4 levels greater than 300 cells/mm3 and treated with Ampligen, were less likely to develop AIDS compared to placebo. Ampligen is also in Phase II trials for the treatment of chronic fatigue syndrome, and has proved active in hepatitis B and renal cell carcinoma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze